Clinical epidemiology applied to rheumatic and musculoskeletal diseases
The prevalence and burden of rheumatic and musculoskeletal diseases (RMDs) are predicted to increase because of the increasingly ageing population, placing greater demands on healthcare budgets. From the patient point of view, RMDs are the first cause of perceived disability. The objectivesof ECAMO team are to identifyrisk factors of poor prognosis, assess specific and effective treatments (both pharmacological and non-pharmacological)and thus decrease disability in patients with RMDs. The ultimate purpose is to providedata to adapt public health policies in the field.
New risk factors and co-morbidities
Evalutation criteria : Structural outcomes and Patients reported outcomes
Therapeutic strategies
Information
Pr. Christian Roux
Director of the teamContact
Denis Basse, administrative assistant
denis.basse@inserm.fr
Major projects
DESIR
National multicentric longitudinal observational cohort
HODOREV project
Improve the attractiveness of physical exercisesWith high morbidity and disability rates, low back pain causes daily difficulties for patients (Vos et al., 2012). It is the number one cause of disability years in the world and the sixth in terms of reducing healthy life expectancy (Hoy et al., 2014). It is also the leading cause of disability at work (Palazzo et al., 2014), with an increasing incidence over the past 30 years.
Other links
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis
Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment